Ionis Pharmaceuticals Q3 Adjusted EPS $(0.85) Beats $(1.07) Estimate, Sales $144.00M Beat $132.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals reported Q3 adjusted EPS of $(0.85), beating the estimate of $(1.07) by 20.56%. The company also reported quarterly sales of $144.00M, surpassing the estimate of $132.90M by 8.35%. However, this represents a 431.25% increase in losses and a 10.00% decrease in sales compared to the same period last year.
November 02, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ionis Pharmaceuticals reported better than expected Q3 results, but with increased losses and decreased sales YoY.
While Ionis Pharmaceuticals beat Q3 estimates, the increased losses and decreased sales compared to the same period last year could potentially offset any positive impact from the earnings beat. This makes the short term impact on the stock price neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100